↓ Skip to main content
What is this page? Embed badge

Programmed Cell Death in Cancer Progression and Therapy

Overview of attention for book
Cover of 'Programmed Cell Death in Cancer Progression and Therapy'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Cell Death: History and Future
  3. Altmetric Badge
    Chapter 2 Caspase Mechanisms
  4. Altmetric Badge
    Chapter 3 The Mitochondrial Death Pathway
  5. Altmetric Badge
    Chapter 4 Apoptotic Pathways in Tumor Progression and Therapy
  6. Altmetric Badge
    Chapter 5 Therapeutic Targeting of Death Pathways in Cancer: Mechanisms for Activating Cell Death in Cancer Cells
  7. Altmetric Badge
    Chapter 6 Programmed Cell Death in Cancer Progression and Therapy
  8. Altmetric Badge
    Chapter 7 Trail Receptors: Targets for Cancer Therapy
  9. Altmetric Badge
    Chapter 8 Rational Design of Therapeutics Targeting the BCL-2 Family: Are Some Cancer Cells Primed for Death but Waiting for a Final Push?
  10. Altmetric Badge
    Chapter 9 Autophagy and Tumor Suppression: Recent Advances in Understanding the Link between Autophagic Cell Death Pathways and Tumor Development
  11. Altmetric Badge
    Chapter 10 Regulation of Programmed Cell Death by the P53 Pathway
  12. Altmetric Badge
    Chapter 11 Regulation of Programmed Cell Death by NF-κB and its Role in Tumorigenesis and Therapy
  13. Altmetric Badge
    Chapter 12 Targeting Proteasomes as Therapy in Multiple Myeloma
  14. Altmetric Badge
    Chapter 13 Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
  15. Altmetric Badge
    Chapter 14 RNA Interference and Cancer: Endogenous Pathways and Therapeutic Approaches
  16. Altmetric Badge
    Chapter 15 Cancer Stem Cells and Impaired Apoptosis
Attention for Chapter 13: Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

wikipedia
6 Wikipedia pages

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
69 Mendeley
Summary Wikipedia Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Chapter number 13
Book title
Programmed Cell Death in Cancer Progression and Therapy
Published in
Advances in experimental medicine and biology, January 2008
DOI 10.1007/978-1-4020-6554-5_13
Pubmed ID
18437899
Book ISBNs
978-1-4020-6553-8, 978-1-4020-6554-5
Authors

Sharmila Shankar, Rakesh K. Srivastava, Shankar, Sharmila, Srivastava, Rakesh K.

Abstract

Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are catalyzed by specific enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. While histones represent a primary target for the physiological function of HDACs, the antitumor effect of HDAC inhibitors might also be attributed to transcription-independent mechanisms by modulating the acetylation status of a series of non-histone proteins. HDAC inhibitors may act through the transcriptional reactivation of dormant tumor suppressor genes. They also modulate expression of several other genes related to cell cycle, apoptosis, and angiogenesis. Several HDAC inhibitors are currently in clinical trials both for solid and hematologic malignancies. Thus, HDAC inhibitors, in combination with DNA-demethylating agents, chemopreventive, or classical chemotherapeutic drugs, could be promising candidates for cancer therapy. Here, we review the molecular mechanisms and therapeutic potential of HDAC inhibitors for the treatment of cancer.

View on publisher site
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 69 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 68 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 23%
Researcher 8 12%
Student > Bachelor 8 12%
Student > Master 6 9%
Student > Doctoral Student 4 6%
Other 10 14%
Unknown 17 25%
Readers by discipline Count As %
Agricultural and Biological Sciences 16 23%
Biochemistry, Genetics and Molecular Biology 13 19%
Medicine and Dentistry 5 7%
Chemistry 5 7%
Immunology and Microbiology 3 4%
Other 8 12%
Unknown 19 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2021.
All research outputs
#7,453,350
of 22,786,087 outputs
Outputs from Advances in experimental medicine and biology
#1,226
of 4,933 outputs
Outputs of similar age
#41,745
of 156,195 outputs
Outputs of similar age from Advances in experimental medicine and biology
#16
of 33 outputs
Altmetric has tracked 22,786,087 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,933 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 156,195 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.